Detection of severe acute respiratory syndrome coronavirus 2 and influenza viruses based on CRISPR-Cas12a
Authors:
- Oraphan MayuramartOMOraphan Mayuramart
- Pattaraporn NimsamerPNPattaraporn Nimsamer
- Somruthai RattanaburiSRSomruthai Rattanaburi
- Naphat ChantaravisootNCNaphat Chantaravisoot
- Kritsada KhongnomnanKKKritsada Khongnomnan
- Jira ChansaenrojJCJira Chansaenroj
- Jiratchaya PuenpaJPJiratchaya Puenpa
- Nungruthai SuntronwongNSNungruthai Suntronwong
- Preeyaporn VichaiwattanaPVPreeyaporn Vichaiwattana
- Yong PoovorawanYPYong Poovorawan
- Sunchai PayungpornSPSunchai Payungporn
Open Access
- 5 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (4) , 400-405
Abstract
Due to the common symptoms of COVID-19, patients are similar to influenza-like illness. Therefore, the detection method would be crucial to discriminate between SARS-CoV-2 and influenza virus-infected patients. In this study, CRISPR-Cas12a-based detection was applied for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, and influenza B virus which would be a practical and attractive application for screening of patients with COVID-19 and influenza in areas with limited resources. The limit of detection for SARS-CoV-2, influenza A, and influenza B detection was 10, 103, and 103 copies/reaction, respectively. Moreover, the assays yielded no cross-reactivity against other respiratory viruses. The results revealed that the detection of influenza virus and SARS-CoV-2 by using RT-RPA and CRISPR-Cas12a technology reaches 96.23% sensitivity and 100% specificity for SARS-CoV-2 detection. The sensitivity for influenza virus A and B detections was 85.07% and 94.87%, respectively. In addition, the specificity for influenza virus A and B detections was approximately 96%. In conclusion, the RT-RPA with CRISPR-Cas12a assay was an effective method for the screening of influenza viruses and SARS-CoV-2 which could be applied to detect other infectious diseases in the future.Keywords
Funding Information
- National Science and Technology Development Agency (P-17-51377)
- Thailand Research Fund (RSA6180035)
- Chulalongkorn University Graduate Scholarship to Commemorate the 72nd Anniversary of His Majesty King Bhumibol Adulyadej
- Ratchada Pisek Sompoch Fund, Faculty of Medicine, Chulalongkorn University (RA(P0)002/63)
- National Research Council of Thailand ((NRCT))
This publication has 11 references indexed in Scilit:
- Direct on-the-spot detection of SARS-CoV-2 in patientsExperimental Biology and Medicine, 2020
- CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumoniaJournal of Drug Targeting, 2020
- SARS-CoV-2 detection with CRISPR diagnosticsCell Discovery, 2020
- Recent progress on the diagnosis of 2019 Novel CoronavirusTransboundary and Emerging Diseases, 2020
- Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19Clinical Microbiology and Infection, 2020
- COVID-19: Time for precision epidemiologyExperimental Biology and Medicine, 2020
- CRISPR–Cas12-based detection of SARS-CoV-2Nature Biotechnology, 2020
- A Novel Coronavirus Emerging in China — Key Questions for Impact AssessmentNew England Journal of Medicine, 2020
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyThe Lancet, 2020
- Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assaysJournal of Virological Methods, 2008